O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018) - Marmorino, F; Cremolini, C; Bergamo, F; Pella, N; Antoniotti, C; Rossini, D; Dell'Aquila, E; Masi, G; Salvatore, L; Loupakis, F; Marcucci, L; Gemma, D; et al.